

Minutes: Confirmed

Guideline Development Group Meeting Diabetes in pregnancy guideline update

Date and Time: Wednesday 1May 2013

10:00 - 16:30

Place: Royal College of Obstetricians and Gynaecologists

London

Present: Rudy Bilous (Chair) (RB) (Present for notes 1 – 9)

Jacqueline Berry (JB) (Present for notes 1 - 9) Aderonke Kuti (AK) (Present for notes 1 - 9) Stacia Smales Hill (SSH) (Present for notes 1 - 9) Michael Maresh (MM) (Present for notes 1 - 9) Judy Shakespeare (JS) (Present for notes 1-7) Katharine Stanley (KS) (Present for notes 1 - 9) Elizabeth Stenhouse (ES) (Present for notes 1 - 9) Diane Todd (DT) (Present for notes 1 - 9)

In attendance:

NCC-WCH staff: Paul Jacklin (PJ) Moira Mugglestone (MMu) Shona Burman-Roy (SBR) Ella Fielding (EF) Cristina Visintin (CV)	(Present for notes 1 – 9) (Present for notes 4 – 9) (Present for notes 1 – 5) (Present for notes 5 – 9) (Present for notes 1 – 9)	
NICE attendees: Palida Teelucknavan (PT)	(Present for notes 1 – 9)	

Observers:

Notes

- 1. RB welcomed the group to the second meeting of this guideline development group (GDG). Apologies were received from Anne Dornhorst and David James.
- RB asked the group for any new declarations of interest. AK declared:

Personal pecuniary: member of the Appraisal Committee meeting - Dapagliflozin- The Technology Appraisal Meeting (NICE)

ES declared:

Personal pecuniary: speaker at the Primary Care live and Public Health honorarium and meeting expenses were paid.

RB declared:

Personal pecuniary: speaker at Diabetes UK annual professional conference (March

2013) expenses were paid by Diabetes UK.

JB declared:

Non-personal pecuniary interest: seconded to King's College London. Will represent King's College London at the Paris lunch of an Insulin Module for type 2 diabetes developed by King's College and sponsored by Abbott. Travel expenses will be paid by Abbott funds held by King's College London.

No other new declarations of interest were received from the GDG members or the other attendees. It was agreed that no interests declared at the meeting or previously warranted exclusion of any GDG members from discussions of evidence or formulation of recommendations at the meeting.

Declarations are kept on record at the NCC-WCH and will be published in the full guideline.

- 3. After a minor amendment the minutes of the previous meeting were accepted as an accurate record of the meeting.
- 4. SBR presented the evidence for 'Gestational diabetes second trimester screening' (the list of Excluded Studies, the Evidence Tables, the GRADE Profiles summarising the evidence and the Evidence Summary and Recommendations). During the presentations the group had an opportunity to discuss the evidence presented and ask questions. Notes of this discussion were made live on screen. This question will be revisited later in the process following the health economic analysis for gestational diabetes.
- 5. SBR presented the draft review protocol relating to interventions for gestational diabetes. The group discussed the technical team's proposed review questions. It was agreed that further discussion would be held with the Chair and the GDG would be advised of any amendments.
- 6. EF presented the evidence for 'Specialist teams' (the list of Excluded Studies, the Evidence Tables, the GRADE Profiles summarising the evidence and the Evidence Summary and Recommendations). During the presentations the group had an opportunity to discuss the evidence presented and ask questions. Notes of this discussion were made live on screen. The GDG decided that the evidence found for this question were not sufficient to support recommendations.
- 7. CV informed the GDG of the relevant dates for the guideline (consultation dates and publication date) and announced to the GDG the meeting dates for 2014.
- 8. MMu informed the GDG that David James has replaced MMu as team leader for this guideline.
- 9. RB informed the GDG about a request for volunteers to comment on a survey from the Health Technology Assessment Programme regarding research needed in hyperglycaemia in pregnancy/gestational diabetes. RB also asked CV to circulate to the GDG members the program of the NIH Consensus Development Diagnosing Gestational Diabetes Mellitus Conference, held in March 2013, Bethesda, USA. There was no other business. RB thanked the participants for attending and closed the meeting.

Date, time and venue of the next meeting

Wednesday, 12 June 2013, 10:00 – 16:30 at the Royal College of Obstetricians and Gynaecologists, London